Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term analogs & derivatives. Found 105 abstracts

no pagination
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. The New England journal of medicine. 2020 Apr 02;382(14):1331-42.
Lyu Z, Kang L, Buuh ZY, Jiang D, McGuth JC, Du J, Wissler HL, Cai W, Wang RE. A Switchable Site-Specific Antibody Conjugate. ACS chemical biology. 2018 Apr 20;13(4):958-64.   PMCID: PMC5910183
Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol. 2018 Jan;41(1):59-64.   PMCID: PMC4769977
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Kantarjian HM, Roboz GJ, Kropf PL, Yee KW, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Oct;18(10):1317-26.   PMCID: PMC5925750
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schonland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 Aug 03;130(5):597-605.
Sato T, Issa JJ, Kropf P. DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harbor perspectives in medicine. 2017 May;7(5).   PMCID: PMC5411681
Ursu O, Gosline SJ, Beeharry N, Fink L, Bhattacharjee V, Huang SC, Zhou Y, Yen T, Fraenkel E. Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens. PLoS One. 2017 Oct;12(10):e0185650.   PMCID: PMC5638242
Weng YL, An R, Cassin J, Joseph J, Mi R, Wang C, Zhong C, Jin SG, Pfeifer GP, Bellacosa A, Dong X, Hoke A, He Z, Song H, Ming GL. An Intrinsic Epigenetic Barrier for Functional Axon Regeneration. Neuron. 2017 Apr 19;94(2):337-346e6.
An Y, Doney AC, Andrade RB, Wheeler SE. Stacking Interactions between 9-Methyladenine and Heterocycles Commonly Found in Pharmaceuticals. Journal of chemical information and modeling. 2016 May 23;56(5):906-14.
Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 Aug;39(4):340-5.   PMCID: PMC4177955
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys. 2016 Mar;94(3):554-60.   PMCID: PMC4876948
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2969-79.   PMCID: PMC5569693
Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT. Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers. Chem Biol. 2015 Nov 19;22(11):1491-504.   PMCID: PMC4701204
Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res. 2015 Jan 15;17:6.   PMCID: 4336497
Drazenovic J, Wang H, Roth K, Zhang J, Ahmed S, Chen Y, Bothun G, Wunder SL. Effect of lamellarity and size on calorimetric phase transitions in single component phosphatidylcholine vesicles. Biochim Biophys Acta. 2015 Feb;1848(2):532-43.
Eidem TM, Lounsbury N, Emery JF, Bulger J, Smith A, Abou-Gharbia M, Childers W, Dunman PM. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28.   PMCID: PMC4356807
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term analogs & derivatives

analogs & derivatives drug therapy Middle Aged Aged Female therapeutic use adverse effects Male Disease-Free Survival pathology administration & dosage mortality metabolism Adult drug effects chemistry genetics 80 and over Aged Deoxycytidine therapy Pancreatic Neoplasms Survival Rate Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols pharmacology Neoplasm Invasiveness Survival Analysis Treatment Outcome Neoplasm Staging antagonists & inhibitors Drug Dose-Response Relationship Drug Administration Schedule Neoplasms secondary Oral Administration Cohort Studies Double-Blind Method diagnosis statistics & numerical data Niacinamide Chemoradiotherapy Retrospective Studies Kidney Neoplasms Prognosis Immunoconjugates Neoplasm Drug Resistance Kaplan-Meier Estimate Intravenous Infusions Azacitidine Indoles Follow-Up Studies Response Evaluation Criteria in Solid Tumors immunology Pyrroles Tumor Cell Line Genetic Epigenesis Diarrhea etiology Adjuvant Chemotherapy Cisplatin Phenylurea Compounds chemically induced Genetic Transcription biosynthesis Cell Proliferation Renal Cell Carcinoma Risk Assessment methods Cell Line Small Molecule Libraries Adenocarcinoma Microbial Sensitivity Tests Radiation Injuries Radiation Scattering Sunitinib Thiourea Maximum Tolerated Dose Fatigue CD19 Antigens Age Factors Coupled phase transition Tdg Reproducibility of Results Hypotension CA-19-9 Antigen blood Camptothecin Electrophoretic Mobility Shift Assay Genotype surgery Small Interfering RNA Multivariate Analysis toxicity Dimyristoylphosphatidylcholine Remission Induction Molecular Models Transitional Cell Carcinoma Breast Neoplasms Switch Genes Mantle-Cell Lymphoma DNA Repair Fallopian Tube Neoplasms Proto-Oncogene Proteins p21(ras) Lipid Bilayers Unilamellar vesicle transplantation Binding Sites Non-Small-Cell Lung Carcinoma Clinical Trials as Topic Adoptive Immunotherapy Immunohistochemistry Peripheral Nerve Injuries Kinetics Phosphatidylcholines 2-Dipalmitoylphosphatidylcholine 1 Differentiation Antigens B7-H1 Antigen Taxoids Incidence bladder cancer deficiency Isomerism high-throughput screening Ribonuclease P Biological Models Muscle Neoplasms Phase Transition DNA Demethylation gemcitabine plus cisplatin Intensity-Modulated Radiotherapy Prospective Studies Enoxaparin Protein Transport synthetic lethality Dihydroxyphenylalanine Amyloidosis cytology Transfer RNA Myeloid Leukemia-Acute doxorubicin Spinal Ganglia Epidermal Growth Factor Receptor Algorithms physiopathology Inhibitory Concentration 50 Neoplastic Gene Expression Regulation Allosteric Regulation Thermodynamics Genetic Polymorphism Urinary Bladder Neoplasms
Last updated on Saturday, July 04, 2020